Document Detail

Clinical and neurohumoral differences between spirapril and captopril in mild to moderate chronic congestive heart failure.
MedLine Citation:
PMID:  9330124     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: This study was done to determine whether the difference in duration of action of the long-acting angiotensin-converting enzyme (ACE) inhibitor spirapril compared with the short-acting ACE inhibitor captopril affects clinical efficacy in patients with congestive heart failure. METHODS AND RESULTS: The effects on exercise capacity, neurohumoral status, and quality of life were studied in 20 patients with mild to moderate congestive heart failure in a double-blind, randomized, comparative study in parallel groups with a duration of 12 weeks. All assessments during the study were performed in the morning, before intake of the study medication, to avoid the expected peak effect of the ACE inhibitors used. Mean peak oxygen consumption (peak Vo2) was 17.4 mL/min/kg (range, 14.2-19.9 mL/min/kg) and mean left ventricular ejection fraction was 28% (range, 13-40%). Exercise duration in the captopril group showed a significant increase after 12 weeks (P < .05) of treatment compared with the spirapril group. Peak oxygen consumption tended only to increase in the captopril-treated patients compared with the spirapril-treated patients. Serum ACE activity was significantly different between the two treatment groups during treatment (P < .0001) and showed only a significant decrease in the spirapril group. There was no difference in improvement of quality of life between the two treatment groups. CONCLUSIONS: This study showed that the effects of the ACE inhibitors spirapril and captopril on exercise capacity are not related to the degree of inhibition of serum ACE activity.
S A van den Broek; P A de Graeff; D J van Veldhuisen; W H van Gilst; H Hillege; H Wesseling; K I Lie
Related Documents :
19528334 - Importance of treadmill exercise time as an initial prognostic screening tool in patien...
15812754 - Treating heart failure with enhanced external counterpulsation (eecp): design of the pr...
16979014 - Heart rate response during exercise predicts survival in adults with congenital heart d...
10921684 - Demand dynamic cardiomyoplasty: mechanograms prove incomplete transformation of the res...
7362134 - Ventilatory muscle training improves exercise capacity in chronic obstructive pulmonary...
10507614 - Relationship between mixed venous oxygen saturation and markers of tissue oxygenation i...
Publication Detail:
Type:  Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Journal of cardiac failure     Volume:  3     ISSN:  1071-9164     ISO Abbreviation:  J. Card. Fail.     Publication Date:  1997 Sep 
Date Detail:
Created Date:  1997-11-14     Completed Date:  1997-11-14     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  9442138     Medline TA:  J Card Fail     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  165-71     Citation Subset:  IM    
Department of Cardiology/Thoraxcenter, University Hospital of Groningen, The Netherlands.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Aldosterone / blood
Angiotensin-Converting Enzyme Inhibitors / therapeutic use*
Captopril / therapeutic use*
Double-Blind Method
Enalapril / analogs & derivatives*,  therapeutic use
Heart Failure / drug therapy*,  enzymology*,  physiopathology
Middle Aged
Norepinephrine / blood
Peptidyl-Dipeptidase A / blood*
Renin / blood
Reg. No./Substance:
0/Angiotensin-Converting Enzyme Inhibitors; 51-41-2/Norepinephrine; 52-39-1/Aldosterone; 62571-86-2/Captopril; 75847-73-3/Enalapril; 83647-97-6/spirapril; EC A; EC
Comment In:
J Card Fail. 1997 Sep;3(3):161-3   [PMID:  9330123 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Assessing influenza immunization rates in Medicare managed care plans: a comparison of three methods...
Next Document:  Safety and efficacy of carvedilol in severe heart failure. The U.S. Carvedilol Heart Failure Study G...